ET-13 * RETROVIRAL REPLICATING VECTOR (RRV)-MEDIATED PRODRUG ACTIVATOR GENE THERAPY WITH CODON-OPTIMIZED NITROREDUCTASE IN EXPERIMENTAL GLIOMA

Stuart Collins

doi:10.1093/neuonc/nou255.13

ET-13 * RETROVIRAL REPLICATING VECTOR (RRV)-MEDIATED PRODRUG ACTIVATOR GENE THERAPY WITH CODON-OPTIMIZED NITROREDUCTASE IN EXPERIMENTAL GLIOMA

Stuart Collins

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Neuro-Oncology
DOIs	https://doi.org/10.1093/neuonc/nou255.13
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cytosine deaminase
Prodrug
Genetic enhancement
Viral vector
Molecular biology
Cytotoxicity
Biology
Glioma
Cancer research
In vitro
Gene
Chemistry
Biochemistry
Recombinant DNA

Access to Document

10.1093/neuonc/nou255.13

https://openalex.org/W2315356525Licence: CC BY-NC-ND

Cite this

@article{ee93d10b19584b948453ce71abdbb47c,

title = "ET-13 * RETROVIRAL REPLICATING VECTOR (RRV)-MEDIATED PRODRUG ACTIVATOR GENE THERAPY WITH CODON-OPTIMIZED NITROREDUCTASE IN EXPERIMENTAL GLIOMA",

keywords = "Cytosine deaminase, Prodrug, Genetic enhancement, Viral vector, Molecular biology, Cytotoxicity, Biology, Glioma, Cancer research, In vitro, Gene, Chemistry, Biochemistry, Recombinant DNA",

author = "Stuart Collins",

year = "2014",

doi = "10.1093/neuonc/nou255.13",

language = "English",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - ET-13 * RETROVIRAL REPLICATING VECTOR (RRV)-MEDIATED PRODRUG ACTIVATOR GENE THERAPY WITH CODON-OPTIMIZED NITROREDUCTASE IN EXPERIMENTAL GLIOMA

AU - Collins, Stuart

PY - 2014

Y1 - 2014

KW - Cytosine deaminase

KW - Prodrug

KW - Genetic enhancement

KW - Viral vector

KW - Molecular biology

KW - Cytotoxicity

KW - Biology

KW - Glioma

KW - Cancer research

KW - In vitro

KW - Gene

KW - Chemistry

KW - Biochemistry

KW - Recombinant DNA

U2 - 10.1093/neuonc/nou255.13

DO - 10.1093/neuonc/nou255.13

M3 - Article

SN - 1522-8517

JO - Neuro-Oncology

JF - Neuro-Oncology

ER -